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Toxoplasmosis is a globally distributed parasitic protozoan disease, caused by Toxo-
plasma gondii. The infection can result in more severe symptoms with potentially life-
threatening in case of immunocompromised individuals. Sulfadiazine and pyrimeth-
amine are the two drugs used as a part of standard therapy for toxoplasmosis. Researchers
have demonstrated the therapeutic effects of medicinal plants for toxoplasmosis, which
can be used as an alternative to standard drug therapy with reduced side effects. Tradi-
tional herbal plants are used by people to cure a large number of parasitic disorders. This
review provides new insights into various medicinal plants that are used traditionally for
the treatment of toxoplasmosis and other parasitic infections, which can be useful as an
alternative treatment option for Toxoplasma gondii infections.1. Introduction
Toxoplasma gondii (T. gondii) is one of the most successful
parasitic protozoa that cause an important zoonosis worldwide.
Although, all warm-blooded animals are vulnerable to the
infection, the ﬁnal hosts of this pathogen are felids. The envi-
ronmentally resistant oocysts shed by infected felids become
infectious upon sporulation and after successful entry into the
body of the meat yielding animals; the pathogen transforms itself
into tachyzoite, bradyzoites and then moves into the muscles and
nervous tissues. Through this mechanism, the pathogen can
effectively transmit the infection, if the infected meat is
consumed by the humans [1–5].
Although, the T. gondii infections are widely prevalent in
human beings, its prevalence rate is not uniform worldwide. It is
observed that the infection rates are higher in Central and South
America and continental Europe (50%–80%), while Alaska has
the lowest prevalence rate of 1%. In the United Kingdom alone,
more than 0.35 million people are infected with the parasite each
year. However, the accurate estimates of the physical and eco-
nomic burden of the disease could not be measured because ofthe limited data available on the overall incidence and severity of
symptoms [6–11].
This review is aimed to discuss the current status and prev-
alence of toxoplasmosis, and also to consider the use of different
medicinal plants as therapeutic agents for toxoplasmosis.
2. Clinical effects of toxoplasmosis
In healthy individuals, toxoplasmosis is generally asymp-
tomatic because of effective immunity; however, the symptoms
may be severe and prove fatal in immunocompromised in-
dividuals, such as those suffering from AIDS. Infected patients
may experience fever or cervical lymphadenopathy, sometimes
associated with myalgia, asthenia, or other nonspeciﬁc clinical
signs. The clinical signs may persist for several weeks, mimicking
infectious mononucleosis, especially since monocytosis can be
observed on blood smears. Although, T. gondii is known to cause
a subclinical infection, a primary infection during pregnancy may
prove fatal and can induce abortions in human [12,13]. The
infection during gestation may result in congenital
toxoplasmosis characterized by chorioretinitis, hydrocephalus,
deafness, and impaired mental development [14]. The parasite is
also known to be associated with psychiatric disorders affecting
behavior, personality and other phenotypic traits [15]. The risk of
infection transmission from mother to the fetus is 30%–45%; ofunder the CC BY-NC-ND license (http://
Ibrahim Al Nasr et al./Asian Paciﬁc Journal of Tropical Medicine 2016; 9(8): 730–734 731these, majority are sub-clinical infections (60%) but 30% of them
may suffer from hydrocephalus, intracerebral calciﬁcation, cho-
rioretinitis and mental retardation. A signiﬁcant number (9%)
results in death of the fetus [16]. Degree of damage to the fetus
depends on the gestational age, and the greatest risk of
congenital toxoplasmosis occurs during the early period of
pregnancy. Whereas the highest level of transmission occurs
during the third trimester of the pregnancy and may cause an
enlarged uterus, but fetal injuries are usually much less severe
during this period [17]. The incidence and consequences of
congenital toxoplasmosis are so severe that, in Austria and
France, it is mandated by law to test seropositivity for T. gondii
in all pregnant women on their ﬁrst visit to the gynecologist [18].
It is worthwhile to claim that even an acute infection can result
in devastating disease in the fetus, AIDS patients, recipients of
organ transplant and patients receiving anti-cancer therapy [19–22].
T. gondii is one of the parasites, which has got broad host
ranges, the very high prevalence rate in humans, including
pregnant women and immune-compromised patients. The
transmission of T. gondii usually occurs by drinking contami-
nated water (oocysts from a feline source), ingesting of infective
oocysts contaminating food product, venereal and congenital
transmission, colostrum and also by ingesting of contaminated
milk [23]. Toxoplasmosis is found to be more common in rural
areas, which might be due to the higher contact of human
body with animals like sheep, goats and cattle either in-house
or farms or by eating unwashed fruits and vegetables, which
might be contaminated with cat feces [18,24].
3. Treatment for toxoplasmosis
An ideal anti-Toxoplasma drug should have parasiticidal
properties against different stages of the parasitic life cycle,
including penetration into cysts. It should show effective pene-
tration through the placental barrier to reach the main sites of
fetal infection and should be free from fetal toxicity and tera-
togenicity. However, none of the currently used drugs fulﬁlled
these criteria. Sulfadiazine and pyrimethamine are the two drugs
used as a part of standard therapy for toxoplasmosis and are
particularly beneﬁcial when the parasite actively multiplies
during the acute stage of the disease. In chronic conditions,
drugs like diaminodiphinylsulfone, atovaquone, spiramicyne,
and clindamycine are used, but these drugs have limited efﬁcacy
due to the emergence of resistant strains and their toxicity to the
fetus during pregnancy. Drugs, such as sulfadiazine (sulfon-
amide) have signiﬁcantly lower parasiticidal activity if it is not
used along with pyrimethamine (dihydrofolate reductase inhib-
itor) [25,26].
If pyrimethamine is used for treatment of T. gondii infection,
it results in the suppression of bone marrow function and can
cause neutropenia. Furthermore, these drug results in folate
depletion that can have detrimental effect on the early fetal
development and therefore, this treatment cannot be used in
congenital toxoplasmosis during the ﬁrst trimester of pregnancy.
The combination of sulfadiazine and pyrimethamine also in-
creases the risk of kidney stones, allergy and other forms of
hepatic or renal complications [27]. Although, new drugs such as
atovaquone, epiroprim (DHFR inhibitor) and ﬂuoroquinolone
antibiotics are effective in vitro and in vivo against T. gondii,
their usage in pregnancy is limited as their safety has not been
established [25]. There is, therefore, a deﬁnite need fordevelopment of more viable treatment options to prevent
toxoplasmosis.
4. Anti-parasitic medicinal plants: history and
success
Humans have been using herbal plants for centuries to treat
various infections with or without knowing their actual proper-
ties. Parasites are responsible probably for more than (1–2)
billion infections, which cause several million deaths every year.
Medicinal plant extracts usually contain complex mixtures
consisting of several classes of secondary metabolites. Quite a
large number of plants have been identiﬁed and researched,
which produce natural products with signiﬁcant anti-parasitic
action [28]. It is out of scope of this review to mention and
discuss all the medicinal plants individually that have been
tested for some sort of anti-parasitic activity.
Traditional medicinal plant extracts have been proven to have
anti-malarial effect. A species of plant Cinchona ofﬁcinalis from
the family of Rubiaceae was one of the ﬁrst drug that was used
to treat malaria in Central and South America. Plant such as
Cinchona ofﬁcinalis and Artemisia annua L. (Asteracea) were
the basis of the development of anti-malarial drugs, including
atovaquone (Tabebuia spp. of family Bignoniaceae) [29].
Curcuma plant species (Zingiberaceae) have been reported to
show anti-parasitic activity against Trypanosoma [30,31]. Plants
like Baccharis retusa (Asteraceae) and Kalanchoe pinnata
(Crassulaceae) were screened and reported to exhibit anti-
leishamanial activity [32]. Researchers have tried analyzing
natural products against Trichomonas species as some of the
strains have become resistant to the standard drugs [33]. A
study conducted in India reported Streblus asper (Moraceae)
to have anti-ﬁlarial activity both in vitro and in vivo [34].
Ascaridole, which is extracted from Chenopodium
ambrosioides (Amaranthaceae) was found to be effective for
hookworm infection [35]. The biological effect of diverse
medicinal plants used to treat various parasitic infections,
including the plant name, parts used and extraction method is
tabulated below (Table 1).
Parasites are usually eukaryotes that share most of the
biochemical and molecular properties with their eukaryotic host
which makes it difﬁcult to ﬁnd an anti-parasitic drug. So this
limitation has always to be kept in mind when we discuss a
medicinal plant against parasitic infections. Several parasites
have become resistant to standard chemotherapy; consequently
medicinal plants can be an alternative choice. Strikingly, there is
no sufﬁcient data available regarding the anti-parasitic activity of
medicinal plant extracts for many of the parasitic infections.
5. Medicinal plants and toxoplasmosis
All these aforementioned treatments are able to reduce or
eliminate the clinical signs and symptoms but do not kill the
parasite or cure the infected host. Hence, the improvement of
safe and affordable drugs to eradicate this disease is of para-
mount importance, which requires extensive scrutiny of com-
pounds having the ability to kill the parasite with least or no
toxicity to humans. Recently, greater prominence has been given
towards ﬁnding alternative medicine to deal with parasitic dis-
eases and consequently, numbers of studies have been per-
formed on the endless number of herbs belonging to a different
Table 1
Medicinal plants used for the treatment of various parasitic infections, including T. gondii.
Plant name Parts used Extraction method Biological effect References
Vernonia colorata Stem and leaves Air-dried, powdered and ethanolic extract Anti-toxoplasmic activity Benoit-Vical F et al [36]
Zingiber ofﬁcinale Stem and leaves Air-dried, powdered and ethanolic extract Anti-toxoplasmic activity Choi KM et al [37]
Sophora ﬂavescens Stem and leaves Air-dried, powdered and ethanolic extract Anti-toxoplasmic activity Choi KM et al [37] and
Youn HJ [38]
Torilis japonica Stem and leaves Air-dried, powdered and ethanolic extract Anti-toxoplasmic activity Youn HJ [38]
Eurycoma longifolia Roots Air-dried, powdered and methanolic extract Anti-toxoplasmic activity Kavitha N et al [39]
Calotropis procera Leaf Air-dried, grounded and ethanolic soak Anti-malarial effect
(Compound CP1-04-61)
Mudi SY and Bukar A [41]
Pulicaria crispa Leaf Air-dried powdered and methanolic extract Anti-cancer and anti-malarial
activity and growth inhibition of
wheat-rootlet activities
Gouda YG et al [42] and
Sathiyamoorthy P et al [52]
Euphorbia retusa Leaf and stems Dried at room temperature, powdered
and methanolic extract
Anti-bacterial activity Refahy LAG [43]
Rumex spinosa Leaf Air-dried methanolic extract
Air-dried chloroformic extract
Anti-fungal (Candida Albicans)
Anti-fungal (Alternaria alternata and
Saccharomyces cerevisiae)
Mandeel Q and Taha A [44]
Ochradenus
baccatus
Leaves and ﬂower Air-dried powdered and methanolic extract Anti-malarial, Anti-leishmanial,
Anti-trypanosomal and
hypocholesterolemic effect
Mothana RA et al [45]
Lycium shawii Leaves Oven-dried, grounded and methanolic extract Hypoglycemic, antiplasmodial
and antitrypanosomal effect





Air-dried ethanolic extract Anti-toxoplasmic activity Al-Zanbagi NA [47,48]
Curcuma longa Stem and leaf Air-dried, water and ethanolic extracts Anti-toxoplasmic activity Al-Zanbagi NA [49,50]
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successful in developing drugs from natural products to treat a
number of parasitic diseases. Over the past ﬁve decades, me-
dicinal plants are being screened systematically to explore their
potential anti-parasitic properties [36–39].
The ﬂora of Saudi Arabia has a rich biodiversity comprising
some of the most valuable medicinal plants around the world.
Some of the medicinal plants are known to possess anti-
microbial, anti-protozoan, immuno-stimulant activities and used
by the traditional healers to cure a series of infections. Calotropis
procera, commonly known as giant milkweed used to treat
leprosy, elephantiasis fever, menorrhagia, malaria and snake bite
in the traditional medicine, is reported to exhibit signiﬁcant anti-
malarial activity against Plasmodium falciparum [40,41].
Pulicaria crispa, a perennial bushy desert plant used to treat
inﬂammation and as an insect repellent is reported to exhibit
anti-tumor and anti-malarial activity. In addition to the cyto-
toxic activity, the plant extracts have been reported to be active
against Leishmania and some ﬁsh bacterial pathogens
[42]. Many species of Euphorbia have been reported to
possess antitumor, antiproliferative, antimicrobial, antipyretic,
analgesic and molluscicidal activity due to the large
variety of compounds, including diterpenes, tannins, alkaloid,
triterpenes and ﬂavonoids. Euphorbia retusa grown in the
wild in Saudi Arabia is stated to retain signiﬁcant
antimicrobial activity [43].
Rumex spinosa commonly known as a devil's thorn is an
annual herbaceous plant known as Hambaz. The methanolic leaf
extract is recorded to display signiﬁcant inhibitory activity
against Candida albicans, while the chloroform extract exhibited
signiﬁcant inhibitory activity against Alternaria alternata and
Saccharomyces cerevisiae [44]. Ochradenus baccatus is one of
the highly valued medicinal plants in Saudi Arabia owing to its
hypocholesterolemic and anti-malaria properties. The methanol
extract of the plant is found to be active against Plasmodium,
Leishmania and Trypanosoma with signiﬁcantly low IC50 values
establishing its antiprotozoal efﬁcacy in vitro [45]. In Saudi
Arabia, Lycium shawii commonly known as ‘Gul Gaider’ is
used for the treatment of diabetes and hypertension by
traditional practitioners. Scientiﬁc studies have demonstrated
that Lycium shawii extract possesses hypoglycemic,
antiplasmodial and antitrypanosomal activity [46].
In a continued effort to improve the efﬁcacy of the therapies
against T. gondii, researchers have evaluated the anti-Toxo-
plasma effects of numerous medicinal plant extracts both in vitro
and in vivo. According to a study done in Western Africa, it was
reported that aqueous extracts of Vernonia colorata exhibited
signiﬁcant anti-Toxoplasma activity with an IC50 of 16.3 mg/L.
The organic solvents, such as dichloromethane, acetone and
ethanol also exhibited a ten-fold gain in activity with IC50 values
as low as 1.7, 2.6 and 2.9 mg/L, respectively. Both the infusion
and decoction of Vernonia colorata extracts exhibited a similar
pattern of activity, which showed a marked inhibition for con-
centrations >10 mg/L and total inhibition at concentrations
>30 mg/L [27]. Choi et al evaluated the anti-Toxoplasma activity
of methanolic extracts of 15 traditional medicines used to treat
T. gondii infections. Of these extracts, signiﬁcant anti-
Toxoplasma activity was observed with Zingiber ofﬁcinale
(EC50 = 0.18 mg/mL) and Sophora ﬂavescens extracts
(EC50 = 0.20 mg/mL) [37].
Ethanol extracts of Torilis japonica and Sophora ﬂavescens
were found to inhibit T. gondii proliferation by 99.3% and98.7%, respectively at a concentration of 156 ng/mL in vitro [29].
Two active fractions of Eurycoma longifolia root extracts,
namely TAF355 and TAF401, are reported to possess
signiﬁcant anti-Toxoplasma activity with IC50 values of
1.125 mg/mL and 1.375 mg/mL, respectively [39].
In Saudi Arabia literature search showed that only ﬁve
studies have been undertaken to evaluate the anti-Toxoplasma
activity of medicinal plants. Al-Zanbagi reported that Oleo-gum
resin of Commiphora molmol used for the treatment of bron-
chitis and in wound healing was evaluated for the anti-Toxo-
plasma activity in mice. It was observed that treatment with 100
and 200 mg/kg/d of the resin reduced the mean number of
tachyzoites by 96.6% and 100.0%, respectively [47,48]. Similarly,
in a murine model, the alcohol extracts of Curcuma longa were
found to exhibit signiﬁcant anti-Toxoplasma activity as
evidenced by 98.6% and 99.2% growth inhibition of
Toxoplasma tachyzoites at 100 and 200 mg/kg/d dose,
respectively [49,50]. In another study, administration of water
extracts of Juniperus procera fruits, leaves and stems
(400 mg/kg/d) exhibited a growth inhibition of tachyzoites by
53.5%, 50.0% and 48.0%, respectively in mice [51].
6. Concluding remarks and perspectives
Many of the medicinal plants exhibit anti-Toxoplasma effects
and have been used by ethnic communities around the world as a
therapeutic agent for combating toxoplasmosis. Medicinal plants
contribute as sources for the production of new medicines and
may enhance the effects of conventional anti-microbials, which
will probably decrease costs and improve the treatment quality
with less-side effects. Continued efforts are needed to exploit the
current medicinal plants, which exhibited anti-Toxoplasma ef-
fects, search for new medicinal plants, and make them the more
accessible alternative to the standard drug therapies.
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